Marco Colasurdo - research works

MMA-OA/LA anastomoses were seen on MRA for 6 (46%) patients, all confirmed on DSA.

Among patients with no MRA evidence of anastomoses, none were found to have anastomoses on DSA.

MMA-OA anastomoses were used as the primary delivery route of IAC for 3 patients (50% of patients with a confirmed presence of MMA-OA anastomoses).

Overall procedural success was 98% (41/42).

Of 22,387 patients (mean age 70.8 years; 29.6% female), 6,497 (29.0%) were readmitted within 90 days across diverse causes.

Non-SDH readmissions carried substantial clinical impact: infection readmissions had the highest mortality (9.6%), exceeding surgical SDH (2.9%) more than 3-fold, and the highest rate of new disability (45.5%) among patients initially discharged with routine self-care.

Among 14,105 unique NIH-funded projects in the Radiation-Diagnostic/Oncology category, 437 of 3434 investigators (12.7%) across all PI roles were clinicians.

Female representation among funded diagnostic radiologists increased from 11 of 64 (17.2%) in 2012 to 30 of 108 (27.8%) in 2025.

Diagnostic radiology funding rose from $39.9 million in 2012 to $87.9 million in 2025, while radiation oncology funding rose from $14.3 million to $67.3 million.

Among 42 new K-series awards, radiation oncology received 28 (66.7%).

A total of 134 901 patients with conservatively managed nontraumatic SDH were identified, of whom 1470 (1.1%) were GLP-1 RA users.

After propensity score matching, 2922 patients remained, with 1461 in each group.

All-cause mortality was also significantly lower for GLP-1 RA users at 1 year (16.1% vs 23.7%, P < .001), reflecting a 33% reduction in hazards.

GLP-1 RA users did not experience different rates of adverse events, such as pancreatitis, gallbladder disease, or ileus/bowel obstruction (all P > .05).